Navigation Links
Women's Sexual Health Company Changes Name in Preparation for Market Entry
Date:11/9/2009

PALO ALTO, Calif., Nov. 9 /PRNewswire/ -- Women's sexual health company, TivaMed, today announced it has changed its name to Viveve as it prepares for a 2010 launch of its Viveve system to OB/GYNs in select U.S. markets.

"Viveve is a name that we believe captures the essence of our company focus on women's sexual health," said Kerry Pope, Viveve's president and chief executive. "Viveve exists for the sole purpose of helping women restore their sense of fulfillment and sexual satisfaction to the level that they enjoyed prior to giving birth."

The company has developed the Viveve procedure, a quick and painless nonsurgical treatment for women who have experienced vaginal looseness and loss of physical sensation that is common to many women after vaginal childbirth. The Viveve procedure uses radiofrequency energy to stimulate the body's natural collagen rebuilding process at the vaginal opening. Viveve has been shown in a clinical study to increase a woman's feeling of vaginal tightness and improve her sexual satisfaction during vaginal intercourse.

Research has shown that many women experience a feeling of looseness and a loss of physical sensation following vaginal childbirth; however, the condition is vastly underreported according to a recent study of more than 500 practicing OB/GYNs(1),(2)

"The problem is two-fold. Most women are uncomfortable speaking with their physicians about vaginal laxity and many physicians feel awkward bringing up this subject in fear of offending women. Many are not fully aware of treatment options that are available," said Sandra Carson, MD, chief of Reproductive Endocrinology at women and Infants Hospital at Brown University. "I expect the Viveve procedure will provide a catalyst for a conversation between patients and their physicians about vaginal laxity."

The Viveve system received FDA clearance in 2008. Three-month follow up results from Viveve's first-in-women trial will be presented later this month at the AAGL annual meeting, November 15 - 19 in Orlando, Florida.

The company's Series A financing was led by GBS Venture Partners and 5AM Ventures. For more information, visit the Viveve Web site at www.viveve.com or phone 650-321-3332.

About 5AM Ventures:

Founded in 2002, 5AM Ventures makes seed and early-stage investments in next-generation life science companies, taking a focused, hands-on approach to company building. The 5AM portfolio is diversified among innovative platforms, spinouts from established biotechnology and pharmaceutical companies, and companies developing near-term products. For more information about 5AM Ventures, please visit www.5amventures.com.

About GBS Ventures:

GBS Venture Partners (GBS) is a leading life science venture capital firm founded in 1996. GBS invests in young businesses developing and commercializing products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for our investors. For more information about GBS, please visit www.gbsventures.com.au.

(1) Barrett G. et al, Women's Sexual Health after Childbirth, British Journal of Obstetrics and Gynaecology, 2000, 107 (2) PP 186-195

(2) Data on file. OB/GYN Alliance, sponsored by Viveve. October 2009

SOURCE Viveve


'/>"/>
SOURCE Viveve
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
2. Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control & Sexual Function in Women
3. Trojan(R) and the National Sexuality Resource Centers Campaign for Sexual Literacy Recognize Outstanding College Reporting on Sexual Health
4. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
5. Adult Circumcision Reduces Risk of HIV Transmission Without Reducing Sexual Pleasure
6. Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples
7. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
11. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
(Date:3/27/2017)... 2017 Therapix Biosciences Ltd. ... in the development of cannabinoid-based drugs, today announced ... the United States of 2,000,000 ... ordinary shares of the Company, at a price ... granted the underwriters a 45-day over-allotment option to ...
Breaking Medicine Technology:
(Date:3/28/2017)... CARTERSVILLE, Georgia (PRWEB) , ... March 28, 2017 ... ... analyst to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, ... been a leader in the real estate valuation industry for more than 40 ...
(Date:3/28/2017)... ... March 29, 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one ... video series titled The Thyroid Secret. Dr. Wentz talked about journey and research recently ... fact that medication IS NOT the only solution to deal with thyroid disease. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... and by physicians, announced today the launch of a free, public-facing tool for ... Cost Analyzer (VCA) was developed to provide comparative information to patients, providers, insurers ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Usually, the impending ... daily wardrobe. However, for those self-conscious about a double chin, this means more anxiety ... ideal solution. , “For most people, a double chin is undesirable,” Dr. Goldman ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm , the ... headquarters to a new, more expansive office space in order to accommodate its ... a distressed office building in Wethersfield, Conn. located at 936 Silas Deane Highway ...
Breaking Medicine News(10 mins):